243 related articles for article (PubMed ID: 36591492)
21. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
22. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
23. The Risk Assessment and Clinical Research of Bile Duct Injury After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Xu H; Yu X; Hu J
Cancer Manag Res; 2021; 13():5039-5052. PubMed ID: 34234549
[TBL] [Abstract][Full Text] [Related]
24. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
[TBL] [Abstract][Full Text] [Related]
25. Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.
Bian LF; Zhao XH; Gao BL; Zhang S; Ge GM; Zhan DD; Ye TT; Zheng Y
World J Gastroenterol; 2020 Aug; 26(30):4442-4452. PubMed ID: 32874056
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
27. Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy.
Xie D; Li Z; Yuan J; Yin X; Chen R; Zhang L; Ren Z
J Hepatocell Carcinoma; 2024; 11():693-705. PubMed ID: 38596594
[TBL] [Abstract][Full Text] [Related]
28. A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy.
Chen S; Gao Y; Li Z; Jia J; Fang M; Wang M; Feng H; Chen Q; Guan W; Wang Z; Gao C
J Cancer; 2018; 9(22):4223-4233. PubMed ID: 30519323
[No Abstract] [Full Text] [Related]
29. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.
Zarisfi M; Kasaeian A; Wen A; Liapi E
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):449-466. PubMed ID: 35543895
[TBL] [Abstract][Full Text] [Related]
31. Development of a novel combined nomogram model integrating Rad-score, age and ECOG to predict the survival of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Liu A; Liu B; Duan X; Yang B; Wang Y; Dong P; Zhou P
J Gastrointest Oncol; 2022 Aug; 13(4):1889-1897. PubMed ID: 36092317
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
34. A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making.
Li J; Li C; Zhu G; Yang J; Zhang Y; Yu Z; Xia J
Ann Transl Med; 2023 Jan; 11(2):68. PubMed ID: 36819596
[TBL] [Abstract][Full Text] [Related]
35. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
[TBL] [Abstract][Full Text] [Related]
36. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
38. Plasma arginase-1 as a predictive marker for early transarterial chemoembolization refractoriness in unresectable hepatocellular carcinoma.
Xia WL; Xu SJ; Guo Y; Zhao XH; Hu HT; Zhao Y; Yao QJ; Zheng L; Zhang DY; Guo CY; Fan WJ; Li HL
Front Oncol; 2022; 12():1014653. PubMed ID: 36212404
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a clinical factors and body fat distribution-based nomogram to predict refractoriness of transarterial chemoembolization in hepatocellular carcinoma.
Li H; Kang W; Rong P
Quant Imaging Med Surg; 2024 Jan; 14(1):447-461. PubMed ID: 38223027
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
